BTV100
AssetAlso Cevimeline Ophthalmic Solution
Muscarinic acetylcholine receptor agonist stimulating tear secretion
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- CHRM1
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Dry eye
Phase 2, Completed, NCT06543303, clinicaltrials.gov, 8 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors7
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 8 Oct 2026, 1 source